Zacks Investment Research upgraded shares of National Research (NASDAQ:NRCIA) from a hold rating to a buy rating in a research report sent to investors on Tuesday. They currently have $33.00 price target on the business services provider’s stock.
According to Zacks, “National Research Corporation offers analytics and insights that facilitate revenue growth, patient, employee, customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. Its services include capture, interpretation, transmittal and benchmarking of critical data elements from various healthcare consumers. National Research Corporation is headquartered in Lincoln, Nebraska. “
Separately, BidaskClub raised National Research from a hold rating to a buy rating in a research report on Wednesday, December 27th.
NASDAQ NRCIA opened at $31.20 on Tuesday. National Research has a 1-year low of $20.19 and a 1-year high of $41.99. The stock has a market capitalization of $762.26, a PE ratio of 53.79 and a beta of 1.68.
National Research (NASDAQ:NRCIA) last released its earnings results on Tuesday, February 13th. The business services provider reported $0.10 earnings per share for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.12). The company had revenue of $29.90 million during the quarter, compared to the consensus estimate of $30.60 million. National Research had a net margin of 19.52% and a return on equity of 27.45%. analysts expect that National Research will post 1.11 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, April 13th. Shareholders of record on Friday, March 30th will be given a dividend of $0.10 per share. This represents a $0.40 dividend on an annualized basis and a yield of 1.28%. The ex-dividend date is Wednesday, March 28th. National Research’s payout ratio is 68.97%.
In other National Research news, Director John N. Nunnelly sold 3,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The stock was sold at an average price of $28.75, for a total transaction of $86,250.00. Following the transaction, the director now owns 33,261 shares in the company, valued at approximately $956,253.75. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Michael D. Hays sold 1,602,399 shares of the company’s stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $39.03, for a total value of $62,541,632.97. Following the transaction, the chief executive officer now owns 5,261,410 shares in the company, valued at approximately $205,352,832.30. The disclosure for this sale can be found here. Insiders have sold a total of 6,870,104 shares of company stock valued at $164,329,548 in the last ninety days. 5.70% of the stock is currently owned by corporate insiders.
Several institutional investors have recently bought and sold shares of NRCIA. Comerica Bank purchased a new stake in shares of National Research in the 4th quarter worth approximately $2,454,000. Renaissance Technologies LLC grew its stake in shares of National Research by 27.1% in the 4th quarter. Renaissance Technologies LLC now owns 289,900 shares of the business services provider’s stock worth $10,813,000 after buying an additional 61,900 shares during the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in National Research during the 4th quarter valued at $1,982,000. Conestoga Capital Advisors LLC boosted its stake in National Research by 7.5% during the 4th quarter. Conestoga Capital Advisors LLC now owns 453,436 shares of the business services provider’s stock valued at $16,913,000 after purchasing an additional 31,505 shares during the last quarter. Finally, State Street Corp boosted its stake in National Research by 12.2% during the 2nd quarter. State Street Corp now owns 157,748 shares of the business services provider’s stock valued at $4,241,000 after purchasing an additional 17,163 shares during the last quarter. Institutional investors own 33.66% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.dispatchtribunal.com/2018/04/07/national-research-nrcia-rating-increased-to-buy-at-zacks-investment-research.html.
About National Research
National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.
Get a free copy of the Zacks research report on National Research (NRCIA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.